




Supplementary figure S2. Median levels with range of inflammatory markers in controls (n=100 for calprotectin, n=141 for S100A12, IL-6 and VEGF) and patients with no PD activity at 12 months (n=30 for calprotectin, S100A12 and VEGF, n=28 for IL-6 (patients on tocilizumab omitted))